Ispectamab Debotansine

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) consisting of ispectamab, a humanized immunoglobulin G1 (IgG1)-kappa monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor (TNF) receptor superfamily, member 17; TNFRSF17) site-specifically conjugated, with a non-cleavable linker, to a maytansinoid payload, with potential antineoplastic activity. Upon administration of ispectamab debotansine, the ispectamab moiety targets and binds to the cell surface antigen BCMA expressed on certain cancer cells. Upon binding and internalization, the maytansinoid payload binds to tubulin, thereby affecting microtubule assembly/disassembly dynamic, and prevents cell division and reduces cell growth of BCMA-expressing cancer cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; TNF ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is overexpressed on malignant plasma cells and plays a key role in plasma survival.

**Synonyms:** - Anti-BCMA ADC CC-99712 - Anti-BCMA Antibody Drug Conjugate CC-99712 - Anti-BCMA Antibody-drug Conjugate CC-99712 - BMS-986352 - CC 99712 - CC-99712 - CC99712 - ISPECTAMAB DEBOTANSINE